Allergy Diagnostics Market by Product & Service (Consumables, Instruments (Immunoassay Analyzer, ELISA Analyzer, Luminometer), Service), Allergen (Food, Inhaled, Drug), Test Type (In Vivo, In Vitro), End User (Diagnostic Laboratories) & Region - Global Forecast to 2026
The global allergy diagnostics market in terms of revenue was estimated to be worth $4.8 billion in 2021 and is poised to reach $8.2 billion by 2026, growing at a CAGR of 11.1% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Factors such as, rising environmental pollution levels, high incidence of allergic diseases, increasing funds by organizations in allergy diagnostics are anticipated to drive growth of the global market.
To know about the assumptions considered for the study, Request for Free Sample Report
Allergy Diagnostics Market Dynamics
Driver: Rising environmental pollution levels
Exposure to indoor and outdoor air pollutants, allergens, and occupational exposure are the major risk factors causing chronic respiratory diseases. The prevalence of allergic disorders among the urban population is higher than those living in rural areas due to the higher exposure to environmental pollutants in cities (as a result of vehicular pollution and industrial activities).
As per the WHO, more than 80% of people living in urban areas are exposed to air quality levels that exceed the WHO safety limits; though this is a global trend, its effects are more severe in the urban areas of low-income countries. This is a major indicator for the growth of the allergy diagnostics market, as air pollution from motor vehicles has been indicated as one of the major risk factors responsible for allergic diseases.
Epidemiological and toxicological research reveals a causal relationship between air pollution and the increased incidence of asthma, allergic rhinitis, and other allergic disorders. Studies have also demonstrated a significant increase in the incidence and exacerbation of asthma in urban locations with elevated PM 2.5 (particulate matter of size 2.5 micrometers or less), nitrogen dioxide, and ozone concentrations.
Research by allergy/immunology community members has shown that pollutants augment immediate and late-phase responses to allergens. Research also indicates that pollutants contribute to disease development, with tobacco smoke and diesel exhaust particles augmenting primary sensitization to antigens, leading to an IgE response. Epidemiologic studies also demonstrate that exposure to ambient air pollutants contributes to increased hospitalizations, decreased lung growth, and disease development.
Opportunity: Use of mHealth in allergy diagnosis
The use of mHealth for the diagnosis of rhinitis is currently limited, with a small number of mHealth tools for allergic rhinitis (AR) diagnosis published in peer-reviewed journals. Recent developments in integrated biosensors, wireless communication, and power harvesting techniques generate a new breed of point-of-care devices. However, AR is a very common disease. Any diagnostic device connected to a smartphone (e.g., peak nasal inspiratory flow meters or intranasal biosensors) would need to be inexpensive to be affordable.
The monitoring of the control of allergic multimorbidity (rhinitis, conjunctivitis, and asthma) has been approached by several apps. Allergymonitor, for example, helps in monitoring the symptoms and medication intake, which is then matched to local pollen concentrations. Similarly, the MASK (Mobile Airways Sentinel Network) MASK-Air, initially called Allergy Diary, uses a visual analog scale (VAS) for eye, nose, & asthma symptoms, work impairment, and a global assessment. The data collected by the users of this app have led to new insights on work productivity, treatment patterns, and phenotypes of allergic diseases.
Incorporating mHealth would enable the allergists and their patients to have a new way of communication via the phone camera, sound recording system, motion sensors, texting, and ultimately by using diagnostic devices and diagnostic algorithms incorporated in the smartphone itself.
Restraint: Premium costs associated with allergy diagnostic instruments
Several allergy diagnostics instruments, such as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers, are periodically updated by market players. As these instruments are equipped with advanced features and functionalities, they are priced at a premium (the price of each instrument varies based on its accuracy, flexibility, and TAT). For instance, immunoassay analyzers cost between USD 10,000 and USD 20,000, while luminometers cost between USD 3,000 and USD 14,000. Semi-automated ELISA readers cost between USD 2,000 and USD 5,000, while fully automated analyzers cost around USD 14,000. Furthermore, maintenance and insurance, laboratory supervision, and overheads (including utilities, space, and administration) are additional expenses required to operate this equipment.
Large hospitals and diagnostic laboratories have a larger share in this market as they have good capital budgets to afford high-volume systems. However, most small laboratories, physicians’ clinics, and independent practitioners have budget constraints owing to which they generally cannot afford large or very large systems. Thus, high fixed-cost requirements are expected to limit the growth of the allergy diagnostics market.
Trend: Reagent rental agreements
Reagent rental agreements are sales agreements between end users (such as hospitals and diagnostic laboratories) and allergy diagnostic product manufacturers. Under these agreements, the end user rents or purchases instruments at a subsidized rate by entering into a reagent-purchase contract with the manufacturer. This mutually beneficial agreement lowers the initial capital investment for the end user while assuring the manufacturer of purchases over a substantial time period. In some cases, analyzers are rented out to the end user at a cost-per-test rate.
Reagent rental agreements and cost-per-test contracts provide significant benefits to laboratories focusing on reducing costs. They also help laboratories avoid major fixed capital expenditures associated with the purchase of new equipment. For high-volume laboratories, these expenditures are substantially higher than those of a standard laboratory. Moreover, with the average contract lasting between 5 and 10 years, this allows laboratories to remain updated with the latest innovations in allergy diagnostics. Some contracts also include service/maintenance expenses in the total cost, providing additional savings for laboratories.
Consumables are expected to hold the largest share of the allergy diagnostics industry, by product & service.
Based on product & service, the global allergy diagnostics market is segmented into consumables, instruments, and services. The consumables segment accounted for the largest share of the global market. The large share of the consumables segment can be attributed to the rising cases of allergies and the requirement for rapid tests to diagnose allergic conditions. The segment is also anticipated to witness significant growth during the forecast period.
In vivo tests are expected to hold the largest share of the allergy diagnostics industry, by test type.
Based on test type, the global allergy diagnostics market is segmented into in vivo tests and in vitro tests. The in vivo tests segment accounted for the largest share of this market. The growth of this segment is mainly driven by the increased adoption of various in vivo tests, such as skin prick tests. These tests are reliable, safe, convenient, and cost-effective, as compared to their conterparts, the in vitro tests.
Inhaled allergens are expected to hold the largest share of the allergy diagnostics industry, by an allergen.
Based on allergens, the global allergy diagnostics market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. The inhaled allergens segment accounted for the largest share of This market due to the rising environmental pollution levels and rising pollen coupled with other factors such as mold, fungus, and dust.
Diagnostic laboratories are expected to hold the largest share of the allergy diagnostics industry, by end user in 2021.
Based on end user, the global allergy diagnostics market is segmented into diagnostic laboratories, hospital-based laboratories, academic research institutes, and other end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the market. The large share of the segment can be primarily attributed to the preference for proper diagnosis from a specialist, rising awareness regarding the management of allergic diseases, and the availability of funds for the operation of independent diagnostic laboratories.
To know about the assumptions considered for the study, download the pdf brochure
North America commanded the largest share of the allergy diagnostics industry in 2021.
Based on region, the global allergy diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America commanded the largest share of this market. The large share of North America can be attributed to the rising incidence of allergies, favorable reimbursement scenarios for allergy diagnosis, and the availability of supportive initiatives by associations.
The major players operating in this market are Thermo Fisher Scientific Inc., (US), Siemens Healthineers (Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation (US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US), Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH (Germany), and Erba Group (UK).
Scope of the Allergy Diagnostics Industry
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$4.8 billion |
|
Estimated Value by 2026 |
$8.2 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 11.1% |
|
Market Driver |
Rising environmental pollution levels |
|
Market Opportunity |
Use of mHealth in allergy diagnosis |
This research report categorizes the allergy diagnostics market into the following segments and subsegments:
By Product & Service
- Consumables
-
Instruments
- Immunoassay Analyzers
- ELISA Analyzers
- Luminometers
- Other Instruments
- Services
By Allergen
- Inhaled Allergens
- Food Allergens
- Drug Allergens
- Other Allergens
By Test Type
-
In Vivo Tests
- Skin Prick Tests
- Patch Tests
- Other In Vivo Tests
- In Vitro Tests
By End User
- Diagnostic Laboratories
- Hospital-based Laboratories
- Academic Research Institutes
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Key Developments of Allergy Diagnostics Industry
- In 2021, Hitachi Chemical Diagnostics, Inc. has been renamed Minaris Medical America, Inc. By uniting the medical business group companies under the name of Minaris Medical, Hitachi aims to strengthen its global presence and expand business operations in the field of in-vitro diagnostics. The companies are a part of Showa Denko Materials Co., Ltd. (renamed from Hitachi Chemical Co., Ltd. on Oct 1, 2020).
- In 2021, PerkinElmer Inc. entered into an agreement with Immunodiagnostic Systems Holdings PLC to acquire the later. The acquisition will enable PerkinElmer Inc. to strengthen its position in the ImmunoDiagnostics (IDS) market. IDS would be incorporated under EUROIMMUN Medizinische LABORDIAGNOSTIKA AG, a company offering allergy products and solutions.
- In 2020, NEOGEN Corporation launched Reveal 3-D for Gluten
- In 2019, Romer Labs Division Holding GmbH opened its APAC Solutions Centre in Singapore. The APAC Solutions Centre features new facilities for food allergen testing.
- In 2018, Omega Diagnostics Group PLC and Immunodiagnostic Systems (IDS) entered into a supply agreement through which Immunodiagnostic Systems (IDS) is the official distributor of allergy tests offered by Omega Diagnostics Group PLC.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global allergy diagnostics market?
The global allergy diagnostics market boasts a total revenue value of $8.2 billion by 2026.
What is the estimated growth rate (CAGR) of the global allergy diagnostics market?
The global allergy diagnostics market has an estimated compound annual growth rate (CAGR) of 11.1% and a revenue size in the region of $4.8 billion in 2021.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 42)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 47)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 BOTTOM-UP APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 6 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT/FACTOR ANALYSIS
TABLE 1 RISKS
2.7 COVID-19 ECONOMIC ASSESSMENT
2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY (Page No. - 60)
FIGURE 10 ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD BILLION)
FIGURE 11 GLOBAL MARKET, BY TEST TYPE, 2021 VS. 2026 (USD BILLION)
FIGURE 12 GLOBAL MARKET, BY ALLERGEN, 2021 VS. 2026 (USD BILLION)
FIGURE 13 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 14 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY, BY REGION, 2021 VS. 2026 (USD BILLION)
4 PREMIUM INSIGHTS (Page No. - 65)
4.1 ALLERGY DIAGNOSTICS MARKET OVERVIEW
FIGURE 15 THE RISING INCIDENCE AND HEAVY ECONOMIC BURDEN OF ALLERGIES IS A KEY FACTOR DRIVING THE MARKET GROWTH
4.2 ASIA PACIFIC: ARKET SHARE, BY ALLERGEN (2020)
FIGURE 16 THE INHALED ALLERGEN SEGMENT DOMINATED THE MARKET IN 2020
4.3 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL ALLERGY DIAGNOSTICS INDUSTRY
FIGURE 17 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 68)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 ALLERGY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND TRENDS
5.2.1 DRIVERS
5.2.1.1 The high incidence and heavy economic burden of allergic diseases
5.2.1.2 Rising environmental pollution levels
5.2.1.3 Increasing funding initiatives in allergy diagnostics
5.2.1.4 Growing access to health insurance
5.2.2 RESTRAINTS
5.2.2.1 Premium costs associated with allergy diagnostic instruments
5.2.2.2 Limited awareness and poor implementation of allergy testing methods
5.2.3 OPPORTUNITIES
5.2.3.1 Use of mHealth in allergy diagnosis
5.2.4 CHALLENGES
5.2.4.1 Shortage of allergists
5.2.5 TRENDS
5.2.5.1 Reagent rental agreements
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 19 DIRECT DISTRIBUTION, THE PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.4 VALUE CHAIN ANALYSIS
FIGURE 20 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
5.5 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
FIGURE 21 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
5.5.1 ROLE IN THE ECOSYSTEM
FIGURE 22 KEY PLAYERS IN THE GLOBAL MARKET ECOSYSTEM
5.6 PRICING ANALYSIS
TABLE 2 AVERAGE SELLING PRICES OF ALLERGY DIAGNOSTICS PRODUCTS
5.7 REGULATORY OVERVIEW
5.7.1 US
TABLE 3 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES
5.7.2 CANADA
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
5.7.3 EUROPE
TABLE 4 EUROPE: CLASSIFICATION OF IVD DEVICES
5.7.3.1 Europe: regulatory process for IVD devices
5.7.4 JAPAN
5.7.4.1 Japan: regulatory process for IVD devices
TABLE 5 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.5 CHINA
TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.6 INDIA
5.7.6.1 India: regulatory process for IVD devices
5.7.7 INDONESIA
TABLE 7 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.7.8 RUSSIA
TABLE 8 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.7.9 SAUDI ARABIA
TABLE 9 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.10 MEXICO
5.7.10.1 Mexico: regulatory process for IVD devices
TABLE 10 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.7.11 BRAZIL
5.7.11.1 Brazil: regulatory process for IVD devices
5.7.12 SOUTH KOREA
TABLE 11 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8 TRADE ANALYSIS
5.8.1 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD THOUSAND)
5.8.2 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2019 (USD THOUSAND)
5.8.3 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020
5.8.4 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020
5.9 PATENT ANALYSIS
5.9.1 PATENT ANALYSIS: LUMINOMETERS
5.10 TECHNOLOGY ANALYSIS
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 HIGH CONSOLIDATION IN THE MARKET TO RESTRICT THE ENTRY OF NEW PLAYERS
5.11.1 DEGREE OF COMPETITION
5.11.2 BARGAINING POWER OF SUPPLIERS
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 THREAT OF SUBSTITUTES
5.11.5 THREAT OF NEW ENTRANTS
5.12 COVID-19 IMPACT ANALYSIS FOR THE ALLERGY DIAGNOSTICS MARKET
5.13 RANGES/ SCENARIOS
5.13.1 GLOBAL MARKET FORECAST
FIGURE 25 REALISTIC SCENARIO OF THE GLOBAL MARKET
FIGURE 26 PESSIMISTIC SCENARIO OF THE GLOBAL MARKET
FIGURE 27 OPTIMISTIC SCENARIO OF THE GLOBAL MARKET
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR ALLERGY DIAGNOSTICS MANUFACTURERS
FIGURE 28 REVENUE SHIFT FOR GLOBAL MARKET
6 ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 98)
6.1 INTRODUCTION
TABLE 13 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 14 GLOBAL MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
6.2 CONSUMABLES
6.2.1 CONSUMABLES ARE THE MOST WIDELY USED PRODUCTS FOR ALLERGY TESTING
TABLE 15 ALLERGY DIAGNOSTICS CONSUMABLES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 16 ALLERGY DIAGNOSTICS CONSUMABLES MARKET, BY REGION, 2020–2026 (USD MILLION)
6.3 INSTRUMENTS
TABLE 17 ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 18 ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 19 ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 20 ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.3.1 IMMUNOASSAY ANALYZERS
6.3.1.1 Immunoassay analyzers are highly preferred for allergy diagnostics
TABLE 21 ALLERGY DIAGNOSTICS FOR IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 22 ALLERGY DIAGNOSTICS FOR IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.3.2 ELISA ANALYZERS
6.3.2.1 The precision offered by ELISA tests to propel the growth of the segment
TABLE 23 ALLERGY DIAGNOSTICS FOR ELISA ANALYZERS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 24 ALLERGY DIAGNOSTICS FOR ELISA ANALYZERS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.3.3 LUMINOMETERS
6.3.3.1 Luminometers are convenient to use, thus leading to their increased adoption
TABLE 25 ALLERGY DIAGNOSTICS FOR LUMINOMETERS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 26 ALLERGY DIAGNOSTICS FOR LUMINOMETERS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.3.4 OTHER INSTRUMENTS
TABLE 27 ALLERGY DIAGNOSTICS FOR OTHER INSTRUMENTS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 28 ALLERGY DIAGNOSTICS FOR OTHER INSTRUMENTS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.4 SERVICES
6.4.1 RISING CASES OF ALLERGIES TO DRIVE THE GROWTH OF THE SERVICES SEGMENT
TABLE 29 ALLERGY DIAGNOSTICS SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 30 ALLERGY DIAGNOSTICS SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION)
7 ALLERGY DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 110)
7.1 INTRODUCTION
TABLE 31 ALLERGY TESTS ADVANTAGES AND LIMITATIONS
TABLE 32 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 33 GLOBAL MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
7.2 IN VIVO TESTS
TABLE 34 IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 35 IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 36 IN VIVO TESTS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 37 IN VIVO TESTS MARKET, BY REGION, 2020–2026 (USD MILLION)
7.2.1 SKIN PRICK TESTS
7.2.1.1 Skin prick tests are the most widely preferred in vivo allergy tests
TABLE 38 SKIN PRICK TESTS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 39 SKIN PRICK TESTS MARKET, BY REGION, 2020–2026 (USD MILLION)
7.2.2 PATCH TESTS
7.2.2.1 Patch tests help in the diagnosis of contact dermatitis, unlike the skin prick test
TABLE 40 PATCH TESTS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 41 PATCH TESTS MARKET, BY REGION, 2020–2026 (USD MILLION)
7.2.3 OTHER IN VIVO TESTS
TABLE 42 OTHER IN VIVO TESTS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 43 OTHER IN VIVO TESTS MARKET, BY REGION, 2020–2026 (USD MILLION)
7.3 IN VITRO TESTS
7.3.1 IN VITRO ALLERGY TESTS ARE SET TO WITNESS SIGNIFICANT GROWTH DURING THE FORECAST PERIOD
TABLE 44 IN VITRO TESTS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 45 IN VITRO TESTS MARKET, BY REGION, 2020–2026 (USD MILLION)
8 ALLERGY DIAGNOSTICS MARKET, BY ALLERGEN (Page No. - 119)
8.1 INTRODUCTION
TABLE 46 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 47 GLOBAL MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
8.2 INHALED ALLERGENS
8.2.1 INHALED ALLERGENS DOMINATED THE MARKET IN 2020
TABLE 48 INHALED ALLERGENS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 49 INHALED ALLERGENS MARKET, BY REGION, 2020–2026 (USD MILLION)
8.3 FOOD ALLERGENS
8.3.1 FOOD ALLERGY IS FOUND TO BE MORE PREVALENT AMONG CHILDREN
TABLE 50 SPECIFIC FOOD-INDUCED ALLERGIC CONDITIONS
TABLE 51 FOOD ALLERGENS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 52 FOOD ALLERGENS MARKET, BY REGION, 2020–2026 (USD MILLION)
8.4 DRUG ALLERGENS
8.4.1 THE DRUG ALLERGY SEGMENT IS EXPECTED TO WITNESS CONSIDERABLE GROWTH DURING THE FORECAST PERIOD
TABLE 53 DRUG ALLERGENS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 54 DRUG ALLERGENS MARKET, BY REGION, 2020–2026 (USD MILLION)
8.5 OTHER ALLERGENS
TABLE 55 OTHER ALLERGENS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 56 OTHER ALLERGENS MARKET, BY REGION, 2020–2026 (USD MILLION)
9 ALLERGY DIAGNOSTICS MARKET, BY END USER (Page No. - 127)
9.1 INTRODUCTION
TABLE 57 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 58 GLOBAL MARKET, BY END USER, 2020–2026 (USD MILLION)
9.2 DIAGNOSTIC LABORATORIES
9.2.1 DIAGNOSTIC LABORATORIES ACCOUNTED FOR THE LARGEST SHARE OF THE END-USER MARKET IN 2020
TABLE 59 GLOBAL MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2016–2019 (USD MILLION)
TABLE 60 GLOBAL MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2026 (USD MILLION)
9.3 HOSPITAL-BASED LABORATORIES
9.3.1 HOSPITAL-BASED LABORATORIES ARE MORE ACCESSIBLE TO PATIENTS AND OFFER RAPID RESULTS
TABLE 61 GLOBAL MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2016–2019 (USD MILLION)
TABLE 62 GLOBAL MARKET FOR HOSPITAL-BASED LABORATORIES, BY REGION, 2020–2026 (USD MILLION)
9.4 ACADEMIC RESEARCH INSTITUTES
9.4.1 GRANTS OFFERED BY ORGANIZATIONS TO SUPPORT THE GROWTH OF THIS SEGMENT
TABLE 63 GLOBAL MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2016–2019 (USD MILLION)
TABLE 64 GLOBAL MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2026 (USD MILLION)
9.5 OTHER END USERS
TABLE 65 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 66 GLOBAL MARKET FOR OTHER END USERS, BY REGION, 2020–2026 (USD MILLION)
10 ALLERGY DIAGNOSTICS MARKET, BY REGION (Page No. - 135)
10.1 INTRODUCTION
TABLE 67 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY, BY REGION, 2016–2019 (USD MILLION)
TABLE 68 GLOBAL MARKET, BY REGION, 2020–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET SNAPSHOT
TABLE 69 NORTH AMERICA: MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 71 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 73 NORTH AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 74 NORTH AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 77 NORTH AMERICA: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 78 NORTH AMERICA: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 79 NORTH AMERICA: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 80 NORTH AMERICA: ALLERGY DIAGNOSTICS INDUSTRY, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 82 NORTH AMERICA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The economic burden associated with allergies is expected to drive the growth of the market
TABLE 83 US: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 84 US: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 85 US: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 86 US: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 87 US: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 88 US: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 89 US: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 90 US: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 91 US: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 92 US: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 93 US: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 94 US: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Rising funding activities in allergy diagnostics to drive the market growth in Canada
FIGURE 30 ALLERGIES, BY TYPE, POPULATION AGED 12 AND OLDER, CANADA (2017)
TABLE 95 CANADA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 96 CANADA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 97 CANADA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 98 CANADA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 99 CANADA: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 100 CANADA: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 101 CANADA: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 102 CANADA: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 103 CANADA: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 104 CANADA: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 105 CANADA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 106 CANADA: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2020–2026 (USD MILLION)
10.3 EUROPE
TABLE 107 EUROPE: ALLERGY DIAGNOSTICS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 108 EUROPE: MARKET, BY REGION, 2020–2026 (USD MILLION)
TABLE 109 EUROPE: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 110 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 111 EUROPE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 112 EUROPE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 113 EUROPE: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 114 EUROPE: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 115 EUROPE: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 116 EUROPE: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 117 EUROPE: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 118 EUROPE: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 119 EUROPE: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 120 EUROPE: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany accounted for the largest share of the EU market in 2020
TABLE 121 COMPARATIVE ANALYSIS OF ALLERGENS
TABLE 122 GERMANY: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 123 GERMANY: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 124 GERMANY: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 125 GERMANY: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 126 GERMANY: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 127 GERMANY: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 128 GERMANY: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 129 GERMANY: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 130 GERMANY: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 131 GERMANY: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 132 GERMANY: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 133 GERMANY: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Increasing prevalence of food anaphylaxis in the UK to support the market growth
TABLE 134 UK: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 135 UK: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 136 UK: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 137 UK: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 138 UK: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 139 UK: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 140 UK: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 141 UK: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 142 UK: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 143 UK: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 144 UK: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 145 UK: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Availability of reimbursements in France to support the growth of the market
TABLE 146 FRANCE: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 147 FRANCE: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 148 FRANCE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 149 FRANCE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 150 FRANCE: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 151 FRANCE: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 152 FRANCE: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 153 FRANCE: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 154 FRANCE: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 155 FRANCE: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 156 FRANCE: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 157 FRANCE: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Presence of allergy diagnostic organizations in Italy to support allergy diagnosis research & demand for products
TABLE 158 ITALY: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 159 ITALY: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 160 ITALY: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 161 ITALY: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 162 ITALY: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 163 ITALY: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 164 ITALY: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 165 ITALY: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 166 ITALY: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 167 ITALY: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 168 ITALY: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 169 ITALY: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 The government undertakes initiatives for the development of the healthcare system in Spain to support the market growth
TABLE 170 SPAIN: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 171 SPAIN: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 172 SPAIN: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 173 SPAIN: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 174 SPAIN: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 175 SPAIN: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 176 SPAIN: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 177 SPAIN: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 178 SPAIN: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 179 SPAIN: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 180 SPAIN: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 181 SPAIN: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.6 REST OF EUROPE (ROE)
TABLE 182 ROE: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 183 ROE: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 184 ROE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 185 ROE: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 186 ROE: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 187 ROE: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 188 ROE: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 189 ROE: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 190 ROE: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 191 ROE: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 192 ROE: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 193 ROE: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2020–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET SNAPSHOT
TABLE 194 ASIA PACIFIC: MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 195 ASIA PACIFIC: MARKET, BY REGION, 2020–2026 (USD MILLION)
TABLE 196 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 197 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 198 ASIA PACIFIC: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 199 ASIA PACIFIC: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 200 ASIA PACIFIC: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 201 ASIA PACIFIC: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 202 ASIA PACIFIC: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 203 ASIA PACIFIC: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 204 ASIA PACIFIC: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 205 ASIA PACIFIC: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 206 ASIA PACIFIC: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 207 ASIA PACIFIC: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 China accounted for the largest share of the allergy diagnostics market in the Asia Pacific
TABLE 208 CHINA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 209 CHINA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 210 CHINA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 211 CHINA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 212 CHINA: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 213 CHINA: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 214 CHINA: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 215 CHINA: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 216 CHINA: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 217 CHINA: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 218 CHINA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 219 CHINA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Increasing prevalence of allergies among children to propel the demand for allergy diagnostics in Japan
TABLE 220 JAPAN: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 221 JAPAN: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 222 JAPAN: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 223 JAPAN: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 224 JAPAN: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 225 JAPAN: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 226 JAPAN: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 227 JAPAN: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 228 JAPAN: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 229 JAPAN: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 230 JAPAN: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 231 JAPAN: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Limited awareness regarding allergy management to limit the growth of the market
TABLE 232 INDIA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 233 INDIA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 234 INDIA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 235 INDIA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 236 INDIA: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 237 INDIA: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 238 INDIA: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 239 INDIA: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 240 INDIA: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 241 INDIA: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 242 INDIA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 243 INDIA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 High prevalence of food allergy to propel the growth of the allergy diagnostics market in Australia
TABLE 244 AUSTRALIA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 245 AUSTRALIA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 246 AUSTRALIA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 247 AUSTRALIA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 248 AUSTRALIA: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 249 AUSTRALIA: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 250 AUSTRALIA: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 251 AUSTRALIA: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 252 AUSTRALIA: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 253 AUSTRALIA: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 254 AUSTRALIA: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 255 AUSTRALIA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 256 ROAPAC: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 257 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 258 ROAPAC: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 259 ROAPAC: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 260 ROAPAC: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 261 ROAPAC: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 262 ROAPAC: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 263 ROAPAC: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 264 ROAPAC: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 265 ROAPAC: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 266 ROAPAC: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 267 ROAPAC: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.5 LATIN AMERICA
TABLE 268 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 269 LATIN AMERICA: MARKET, BY REGION, 2020–2026 (USD MILLION)
TABLE 270 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 271 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 272 LATIN AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 273 LATIN AMERICA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 274 LATIN AMERICA: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 275 LATIN AMERICA: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 276 LATIN AMERICA: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 277 LATIN AMERICA: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 278 LATIN AMERICA: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 279 LATIN AMERICA: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 280 LATIN AMERICA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 281 LATIN AMERICA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Brazil accounted for the largest share of the allergy diagnostics market in Latin America
TABLE 282 BRAZIL: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 283 BRAZIL: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 284 BRAZIL: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 285 BRAZIL: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 286 BRAZIL: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 287 BRAZIL: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 288 BRAZIL: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 289 BRAZIL: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 290 BRAZIL: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 291 BRAZIL: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 292 BRAZIL: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 293 BRAZIL: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 The availability of allergy education training to support the growth of the market in Mexico
TABLE 294 MEXICO: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 295 MEXICO: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 296 MEXICO: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 297 MEXICO: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 298 MEXICO: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 299 MEXICO: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 300 MEXICO: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 301 MEXICO: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 302 MEXICO: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 303 MEXICO: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 304 MEXICO: ALLERGY DIAGNOSTICS INDUSTRY, BY END USER, 2016–2019 (USD MILLION)
TABLE 305 MEXICO: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
10.5.3.1 The rising concentration of pollen in the environment is expected to propel the demand for allergy diagnostics in the region
TABLE 306 ROLATAM: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 307 ROLATAM: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 308 ROLATAM: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 309 ROLATAM: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 310 ROLATAM: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 311 ROLATAM: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 312 ROLATAM: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 313 ROLATAM: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 314 ROLATAM: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 315 ROLATAM: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 316 ROLATAM: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 317 ROLATAM: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA (MEA)
10.6.1 RISING INCIDENCES OF ALLERGY RHINITIS TO SUPPORT THE MARKET GROWTH IN THE MEA REGION
TABLE 318 MEA: ALLERGY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 319 MEA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 320 MEA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 321 MEA: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 322 MEA: MARKET, BY TEST TYPE, 2016–2019 (USD MILLION)
TABLE 323 MEA: MARKET, BY TEST TYPE, 2020–2026 (USD MILLION)
TABLE 324 MEA: IN VIVO TESTS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 325 MEA: IN VIVO TESTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 326 MEA: MARKET, BY ALLERGEN, 2016–2019 (USD MILLION)
TABLE 327 MEA: MARKET, BY ALLERGEN, 2020–2026 (USD MILLION)
TABLE 328 MEA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 329 MEA: ALLERGY DIAGNOSTICS MARKET, BY END USER, 2020–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 237)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE MARKET
11.3 REVENUE ANALYSIS
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN THE ALLERGY DIAGNOSTICS MARKET
11.4 MARKET SHARE ANALYSIS
FIGURE 33 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY SHARE ANALYSIS (2020)
TABLE 330 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT (MAJOR PLAYERS)
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 34 VENDOR DIVE: GLOBAL ALLERGY DIAGNOSTICS INDUSTRY
11.6 COMPETITIVE LEADERSHIP MAPPING (START-UPS AND SMES)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 35 GLOBAL ALLERGY DIAGNOSTICS INDUSTRY: VENDOR DIVE MATRIX FOR SMES AND START-UPS, 2020
11.7 COMPANY FOOTPRINT
TABLE 331 COMPANY FOOTPRINT
TABLE 332 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 333 COMPANY TEST TYPE FOOTPRINT
TABLE 334 COMPANY GEOGRAPHICAL FOOTPRINT
11.8 COMPETITIVE SCENARIO AND TRENDS
11.8.1 DEALS
TABLE 335 DEALS, JANUARY 2017-JULY 2021
11.8.2 PRODUCT LAUNCHES
TABLE 336 PRODUCT LAUNCHES, JANUARY 2017-JULY 2021
11.8.3 EXPANSIONS
TABLE 337 EXPANSIONS, JANUARY 2017-JULY 2021
11.8.4 OTHER DEVELOPMENTS
TABLE 338 OTHER DEVELOPMENTS, JANUARY 2017-JULY 2021
12 COMPANY PROFILES (Page No. - 252)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 THERMO FISHER SCIENTIFIC INC.
TABLE 339 THERMO FISHER SCIENTIFIC INC. INC: BUSINESS OVERVIEW
FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
12.1.2 DANAHER
TABLE 340 DANAHER: BUSINESS OVERVIEW
FIGURE 37 DANAHER: COMPANY SNAPSHOT (2020)
12.1.3 MINARIS MEDICAL AMERICA, INC.
TABLE 341 MINARIS MEDICAL AMERICA, INC.: BUSINESS OVERVIEW
FIGURE 38 HITACHI CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2019)
12.1.4 SIEMENS HEALTHINEERS AG
TABLE 342 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020)
12.1.5 EUROFINS SCIENTIFIC
TABLE 343 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
12.1.6 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
TABLE 344 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: BUSINESS OVERVIEW
FIGURE 41 PERKINELMER: COMPANY SNAPSHOT (2020)
12.1.7 BIOMÉRIEUX SA
TABLE 345 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 42 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020)
12.1.8 STALLERGENES GREER LTD
TABLE 346 STALLERGENES GREER LTD.: BUSINESS OVERVIEW
12.1.9 ROMER LABS DIVISION HOLDING GMBH
TABLE 347 ROMER LABS DIVISION HOLDING GMBH: BUSINESS OVERVIEW
FIGURE 43 DSM ROYAL: COMPANY SNAPSHOT (2020)
12.1.10 NEOGEN CORPORATION
TABLE 348 NEOGEN CORPORATION: BUSINESS OVERVIEW
FIGURE 44 NEOGEN CORPORATION: COMPANY SNAPSHOT (2020)
12.1.11 HOLLISTERSTIER ALLERGY
TABLE 349 HOLLISTERSTIER ALLERGY: BUSINESS OVERVIEW
FIGURE 45 JUBILANT PHARMA LIMITED: COMPANY SNAPSHOT (2020)
12.1.12 OMEGA DIAGNOSTICS GROUP PLC
TABLE 350 OMEGA DIAGNOSTICS GROUP PLC : BUSINESS OVERVIEW
FIGURE 46 OMEGA DIAGNOSTICS GROUP PLC: COMPANY SNAPSHOT (2020)
12.2 OTHER PLAYERS
12.2.1 HOB BIOTECH GROUP CORP., LTD.
TABLE 351 HOB BIOTECH GROUP CORP., LTD.: BUSINESS OVERVIEW
12.2.2 HYCOR BIOMEDICAL
TABLE 352 HYCOR BIOMEDICAL: BUSINESS OVERVIEW
12.2.3 LINCOLN DIAGNOSTICS, INC.
TABLE 353 LINCOLN DIAGNOSTICS, INC.: BUSINESS OVERVIEW
12.2.4 R-BIOPHARM AG
TABLE 354 R-BIOPHARM AG: BUSINESS OVERVIEW
12.2.5 ASTRA BIOTECH GMBH
TABLE 355 ASTRA BIOTECH GMBH: BUSINESS OVERVIEW
12.2.6 ERBA GROUP
TABLE 356 ERBA GROUP: BUSINESS OVERVIEW
12.2.7 AESKU.GROUP GMBH
TABLE 357 AESKU.GROUP GMBH: BUSINESS OVERVIEW
12.2.8 ACON LABORATORIES, INC.
TABLE 358 ACON LABORATORIES, INC.: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 292)
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the allergy diagnostics market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as allergy diagnostics products manufacturers, vendors, distributors, and allergists from hospitals and clinics were consulted for this report. The demand side of this market is characterized by the high incidence of allergic diseases and associated heavy economical burden, rising environmental pollution levels, increasing funds by organizations in allergy diagnostics, and the increasing access to healthcare insurance. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Allergy Diagnostics Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the allergy diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research.
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the allergy diagnostics industry.
Report Objectives
- To define, describe, and forecast the allergy diagnostics market based on product & service, allergen, test type, end user, and region.
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, trends, opportunities, and challenges, and COVID-19 Impact Analysis)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall allergy diagnostics market
- To analyse market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the market segments in four geographical regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
- To profile the key players and comprehensively analyse their product portfolios, market positions, and core competencies.
- To track and analyse competitive developments such as product launches, deals and expansions in the allergy diagnostics market.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Geographic Analysis: Further breakdown of the allergy diagnostics market into specific countries/regions in the Rest of Europe, Rest of Asia Pacific, and the Middle East & African countries
-
Company Information: Detailed analysis and profiling of additional market players (up to 5) inclusive of:
- Business Overview
- Financial Information
- Product Portfolio
- Developments (last three years)
Generating Response ...
Growth opportunities and latent adjacency in Allergy Diagnostics Market